- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04217486
ROM Outcomes in Patients Undergoing a Primary TKA
September 14, 2021 updated by: Arthur Malkani, University of Louisville
Will Visual Affirmation of Knee Range of Motion (ROM) Affect Patient Outcomes in Patients Undergoing a Primary Total Knee Arthroplasty (TKA)? A Prospective, Randomized Study.
The goal of this prospective, randomized study is to compare the outcomes of patients undergoing primary TKA after photographing final knee range of motion immediately post-operatively and sharing these photographs with patients at their first follow-up appointment versus a group that does not see a photograph.
Study Overview
Status
Completed
Conditions
Detailed Description
The goal of this prospective, randomized study is to compare the outcomes of patients undergoing primary total knee arthroplasty (TKA) after photographing final knee range of motion immediately postoperatively and sharing these photographs with patients at their first follow-up appointment versus a group that does not see a photograph.
The knee will be photographed in maximum flexion and extension.
The primary objectives will be to compare the range of motion of the operative knee at 2 weeks and 6 weeks postoperatively.
In the investigator's institution, patients who have failed to achieve 90 degrees of flexion at a postoperative period of 6 weeks undergo manipulation of the knee under anesthesia (MUA).
The investigators will also measure how many patients require MUA in the photograph group and non-photograph group.
MUA will be performed if patients fail to achieve 90 degrees of flexion at 6 weeks post-op.
Study Type
Interventional
Enrollment (Actual)
158
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Jewish Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is between the age of 22-89
- Patient is scheduled to undergo a unilateral, cementless primary TKA, secondary to osteoarthritis
- Patient agrees to participate as a study subject and signs the Informed Consent and Research Authorization documents
- Patient is able to read and speak English.
Exclusion Criteria:
- Patient is under the age of 22 or over the age of 89
- Patient has preoperative stiffness/contracture of the knee secondary to post-traumatic arthritis
- Patient is scheduled to undergo a bilateral TKA surgery
- Patient is unable to read and speak English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - will be shown their photograph at 2 weeks post-operative.
40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
|
Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
|
Active Comparator: B - will not be shown their photograph
40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will not be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
|
Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee Society Score
Time Frame: outcome measure will be taken preoperatively (4-6 weeks prior to date of surgery)
|
Knee Society Score.
The score is on a scale from 0-100.
A higher value represents a better outcome.
|
outcome measure will be taken preoperatively (4-6 weeks prior to date of surgery)
|
Knee Society Score
Time Frame: outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Knee Society Score.
The score is on a scale from 0-100.
A higher value represents a better outcome.
|
outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Active range-of-motion (ROM)
Time Frame: outcome measure will be taken preoperatively (4-6 weeks prior to date of surgery)
|
Active ROM (range-of-motion) as measured by a goniometer (range of 0-135 degrees)
|
outcome measure will be taken preoperatively (4-6 weeks prior to date of surgery)
|
Active range-of-motion (ROM)
Time Frame: outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Active ROM (range-of-motion) as measured by a goniometer (range of 0-135 degrees)
|
outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
total length of hospital stay
Time Frame: outcome measure will be taken at 2 weeks postoperatively
|
total length of hospital stay as defined by number of days from date of surgery to date of discharge
|
outcome measure will be taken at 2 weeks postoperatively
|
Operative Time
Time Frame: outcome measure will be taken at 2 weeks postoperatively
|
Total Operative Time as defined in minutes
|
outcome measure will be taken at 2 weeks postoperatively
|
Estimated Blood Loss (EBL)
Time Frame: outcome measure will be taken at 2 weeks postoperatively
|
Estimated Blood Loss as defined by the amount of intraoperative blood loss measured in cubic centimeters (cc).
|
outcome measure will be taken at 2 weeks postoperatively
|
WOMAC Score
Time Frame: outcome measure will be taken preoperatively (4-6 weeks prior to date of surgery)
|
WOMAC score.
The score is on a scale from 0-100.
In contrast to the Knee Society Score, on the WOMAC a lower value represents a better outcome
|
outcome measure will be taken preoperatively (4-6 weeks prior to date of surgery)
|
WOMAC Score
Time Frame: outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
WOMAC score.
The score is on a scale from 0-100.
In contrast to the Knee Society Score, on the WOMAC a lower value represents a better outcome
|
outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Incidence of loss of knee motion requiring an MUA (manipulation under anesthesia)
Time Frame: outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Loss of knee motion is defined as failure to achieve greater than 100 degrees of active flexion.
Manipulation under anesthesia is an outpatient procedure performed by orthopedic surgeon to help improve patient's range-of-motion.
|
outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Tourniquet time
Time Frame: outcome measure will be taken at 2 weeks postoperatively
|
Total Tourniquet Time is the number of minutes that the tourniquet is inflated, as defined in minutes.
|
outcome measure will be taken at 2 weeks postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with postoperative complications
Time Frame: outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Number of Participants with postoperative complications.
A postoperative complication is defined as any diagnosis or condition that necessitates a re-operation or procedure on the surgical knee
|
outcome measure will be taken 6 weeks (± 2 weeks) postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 4, 2020
Primary Completion (Actual)
September 21, 2020
Study Completion (Actual)
May 31, 2021
Study Registration Dates
First Submitted
December 30, 2019
First Submitted That Met QC Criteria
December 30, 2019
First Posted (Actual)
January 3, 2020
Study Record Updates
Last Update Posted (Actual)
September 16, 2021
Last Update Submitted That Met QC Criteria
September 14, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19.1179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
-
National Yang Ming UniversityFar Eastern Memorial HospitalCompletedMedial Knee OsteoarthritisTaiwan
-
Hanlim Pharm. Co., Ltd.CompletedKnee OsteoarthritisKorea, Republic of
Clinical Trials on Patient will be shown a photograph of their knee at 2 weeks postop
-
Memorial Sloan Kettering Cancer CenterCelgene CorporationCompletedLeukemia | Chronic Lymphocytic LeukemiaUnited States
-
Technical University of MunichCompletedGastrointestinal Stromal TumorsGermany
-
Nantes University HospitalCompletedPatients Receiving Animal-derived Bioprosthetic Heart ValvesFrance, Canada, Italy, Spain
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBreast Cancer | Atrophic VaginitisUnited States
-
Memorial Sloan Kettering Cancer CenterJohns Hopkins University; Brown University; University of Southern California; Weill... and other collaboratorsRecruitingBreast Cancer | Rare CancerUnited States
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States
-
University of EdinburghNHS LothianCompletedHeart Disease | Vascular DiseaseUnited Kingdom
-
Marmara UniversityRecruitingCoronary Artery Bypass Graft SurgeryTurkey
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed